The difference in cancer detection

Cxbladder - The difference in cancer detection

Cxbladder is a non-invasive genomic urine test optimised for the detection and management of bladder cancer. The test combines clinical risk factors with gene expression markers to quickly and accurately detect the presence or absence of bladder cancer. Cxbladder comes as a suite of tests, each optimised for a different point in the patient journey.


Cxbladder Detect

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

Cxbladder Triage

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

Cxbladder Resolve

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Cxbladder Monitor

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.


Browse our library of clinical publications.



  • A suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with haematuria, or surveilling for bladder cancer recurrence
  • Facilitates early detection of bladder cancer and helps rule out bladder cancer-free patients 
  • Identifies those patients who are likely have aggressive or more advanced bladder cancer
  • Effective adjunct to cystoscopy
  • Improves overall detection accuracy in combination with others tests and procedures. Resolves atypical cytology and equivocal cystoscopy
  • Can be used to replace other urine-based tests or replace the need for CT / IVP in some instances
  • Easy to use - a complete sampling system is provided for collection and shipment of the patient's urine to our laboratory
  • Provides the option of in-home sampling to simplify and streamline the bladder cancer testing process


Browse our library of clinical publications.

Cxbladder is available in the following countries

  • Australia – Through Pacific Edge PTY Australia
  • New Zealand – Through Pacific Edge Diagnostics NZ
  • Singapore - Through Pacific Edge Diagnostics Singapore
  • United States – Through Pacific Edge Diagnostics USA

For further information on Cxbladder, please visit:

Browse our library of clinical publications.


Pacific Edge is responsible for the development and determination of the performance characteristics for Cxbladder. Because Cxbladder is a Laboratory Developed Test (LDT), Cxbladder has not been cleared or approved by the US Food and Drug Administration (FDA).